Topics

Eisai, Biogen Discontinue Phase III Alzheimer\'s Trials

04:36 EDT 13 Sep 2019 | Contract Pharma

Data Safety Monitoring Board recommended to discontinue trials due to unfavorable risk-benefit ratio

Original Article: Eisai, Biogen Discontinue Phase III Alzheimer\'s Trials

NEXT ARTICLE

More From BioPortfolio on "Eisai, Biogen Discontinue Phase III Alzheimer\'s Trials"

Quick Search